GARDNER, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of…
– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity…
BETHESDA, MD, Feb. 20, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the “Company”) (NASDAQ: HWH), a purpose-driven lifestyle company, today…
Company through its co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax…
- Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate…
OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic…
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company…
ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company…
– Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions – – Reflects positive preliminary Phase…
The FDA has granted Breakthrough Therapy Designation for SkinTE based on key positive data from the Phase II study in…